Phenobarbital and primidone frequently have adverse effects on mental functions. Therefore, an attempt was made to taper barbiturates in 85 patients out of a resident population with epilepsy and intellectual disability who were selected according to clinical criteria. The objectives were to reduce the use of barbiturates, to improve the patients' cognitive and psychological state, and to reduce polypharmacy while avoiding seizure exacerbation. Four months after complete withdrawal changes in seizure frequency were assessed as well as changes in cognitive abilities, psychological state and behaviour (using the clinical global impression scale). In 13 patients the tapering failed due to complications (seizure increase in 11 patients). In 72 patients the barbiturate was completely withdrawn (mean duration of tapering: 393 days). Cognitive improvement was achieved in 17 patients (23.6%), 5 patients (6.9%) deteriorated. Seizure frequency remained unchanged in 33 patients (45.8%), in another 15 patients (20.8%) the seizure frequency decreased. Reduction in polypharmacy was obtained in 61 patients (84.7%). In an overall judgement (clinical global impression scale) of cognitive abilities AND seizure control, 25 patients (34.7%) were improved. 31 patients (43.1%) remained unchanged while 12 patients deteriorated (4 patients: impossible to judge). For statistical analysis three outcome groups were defined: the improved group (N = 25), the unchanged group (N = 31), and the deteriorated/failed group (N = 25) consisting of the 12 deteriorated patients plus the 13 patients in whom tapering failed. Stepwise logistic regression revealed a history of an attempt to withdraw phenobarbital/primidone (p = 0.017; OR 3.8), age (p = 0.012) and seizure frequency (marginally significant: p = 0.097) as outcome predictors. Older age was associated with better outcome. A high seizure frequency before tapering was related to good outcome, while seizure freedom and a history of failed withdrawal were associated with deterioration/failure. Outcome did not depend on duration of barbiturate therapy, dosage or serum concentration, comedication, reduction rate, degree of intellectual disability, or epilepsy syndrome. In summary, the number of barbiturate medications has been considerably reduced, but the principal aim of the project, to relieve patients from assumed barbiturate side effects, has been achieved only in one out of four patients.
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light onto the neurophysiologic basis of these effects: P300 latencies (auditory event-related potentials, a measure of cognitive functions like decision-making, stimulus processing and memory) were found to be delayed in seizure free children on monotherapy with PB but not with CBZ or VPA. 14 As a consequence of these disadvantages, the use of barbiturates declined over the years as was shown in several studies on the long-term course of epilepsy and epilepsy treatment. [15] [16] [17] [18] According to most clinicians, barbiturates are no longer a treatment of first choice, especially not in children and in patients with intellectual disability. 12, 13, 19, 20 On the other hand, PB has also some advantages: It is effective in a broad spectrum of focal as well as generalised epilepsy syndromes (but not in classical absences). Its long half life can be favourable in patients who tend to miss medication doses. And last but not least, in a more global perspective, the low prize makes it affordable even in parts of the world with limited resources. 21, 22 An excellent delineation of the pros and cons of PB is given by Kwan. 23 In our organisation, which has a long tradition in epilepsy treatment, PB (and to a less extent PRM) has been broadly used for decades. When newer AEDs became available (CBZ and VPA since the sixties, several new AEDs since the nineties of the last century), the use of the barbiturates gradually abated. Nevertheless, an investigation in antiepileptic therapy regimens in our organisation carried out in 2002 revealed that as many as 229 resident patients (33.9%) were being treated with PB or PRM (alone or in combination with other AEDs). This rate seemed relatively high, also in comparison with data from other organisations. [24] [25] [26] Therefore, we started an attempt to withdraw barbiturates in our resident population; this paper reports the experience made.
This project had the following objectives: To reduce the use of barbiturates; to improve the patients' cognitive and psychological state by eliminating supposed PB side effects; to avoid seizure exacerbation (or even achieve seizure decrease) and other complications; to reduce polypharmacy.
Patients and methods
In 2004 we reviewed the 229 patients who had been on barbiturate therapy in 2002. Thirteen patients had died and 3 had left our organisation. One patient could not be reviewed for an individual reason. Twenty-one patients were no longer on PB. Thus, 191 patients on barbiturate therapy (184 on PB, 7 on PRM) were left in 2004.
A thorough individual case evaluation was undertaken on all of these 191 patients by the first author together with the staff neurologist or psychiatrist in charge for the individual patient. The individual medical case records (which are voluminous in many cases) were carefully studied. Present and past seizure records were evaluated as well as notes on effects and side effects of all antiepileptic drugs administered. A synopsis on AED dosages and serum concentrations back to 1977, provided by the antiepileptic drug laboratory, was also used to get an overview over treatment history. Important questions and considerations in the evaluation process included: The duration of PB treatment; information on effects when PB had been started; outcome of earlier attempts to taper PB; availability of alternative therapeutic options; interactions between PB and concomitant medication. An estimation of the risk of seizure relapse or increase was made using all available information on seizure frequency in earlier years, course of earlier medication changes, and effect when PB was initially added to the patient's regimen. The potential consequences of a possible seizure relapse or increase for the respective patient were also considered. Special caution was applied in seizure free patients 27 and in the elderly above 70 years of age. Finally, the first author together with the staff neurologist/psychiatrist in charge came to an individual decision whether to maintain or to taper PB/PRM. This decision comprehended all relevant medical aspects and also the patients' whole life situation. For the group designed to taper PB/PRM, the first author and the staff neurologist/psychiatrist in charge also defined an individual stepwise reduction pattern for each patient according to his or her medical and personal circumstances. Possible reasons for slow tapering were, among others: patient known to be prone to seizure increase on medication change; history of seizure-related falls, danger of bone fractures. Possible reasons for a faster tapering included: lack of initial PB efficacy; no increased risk of status epilepticus, falls or fractures. PB was then reduced step by step by the neurologist/psychiatrist in charge, who held regular clinics (approx. biweekly to once in 6 weeks) with the patients and their immediate care-takers. When problems arose, they were discussed between the physician in charge and the first author. The original reduction pattern was revised when required. Adaptations of the concomitant medication were made when clinically necessary. Patients lived their normal lives during the tapering procedure (most of them worked in a sheltered workshop or attended a senior persons' day centre). Four months after complete PB withdrawal a post-evaluation was made. When medication adjustments were still ongoing or the seizure frequency was not yet clear after 4 months the first author could extent this period to 6 months.
For the assessment of changes in cognitive abilities, psychological status and behaviour the clinical global impression scale (CGI) was applied. 28 The questionnaire was filled in by the staff neurologist/psychiatrist, after consultation with the care-takers and, where possible, with the patient. The slightly adapted tool included the following questions: ''Is the patient impaired (with respect to cognition/psychological state/behaviour) by his/her antiepileptic medication?'' (to be answered before and after withdrawal) ''Are there any changes in cognition/psychological state/behaviour?'' An overall judgement: ''What is the overall clinical effect of the intervention, also considering possible changes in seizure frequency or severity?'' (to be answered after withdrawal) Statistical analysis (Fisher's exact test, one-sided; KruskalWallis test) was performed by one of the authors (T.M.) using SPSS version 15.
Results
The clinical decision achieved as described above was to maintain the barbiturate (PRM: 1 patient) in 93 persons (the Fig. 1 . Overview. maintenance group; Fig. 1 ). Clinical characteristics of these patients are given in Table 1 . The reasons for maintaining PB are given in Table 2 .
In 98 patients the decision was to taper the barbiturate (PRM: 6). However, 13 of these patients (2 on PRM) had to be excluded for a variety of reasons: 5 patients and 1 legal representative disagreed tapering for fear of complications. In 2 cases a series of medical complications unrelated to epilepsy delayed the tapering very much or rendered it impossible. Another patient underwent epilepsy surgery with promising results and, therefore, tapering was not carried out. Two seizure free patients (one on PB monotherapy) had to be taken out of the evaluation due to an extremely slow withdrawal schedule (e.g., 15 mg/3-6 months). Two patients died during the trial, both obviously unrelated to epilepsy or antiepileptic treatment. 3 See Table 1 for characteristics of the excluded patients. The remaining 85 patients (PRM: 4) will be referred to as the taper group (Fig. 1 ).
In 13 patients (PRM: 2) of the taper group, the tapering had to be aborted (12 patients) or reversed (PB re-introduced; one patient) due to complications (Table 1, tapering failed group; Fig. 1 ).
In 72 patients the barbiturate (PRM: 2) was completely withdrawn (the withdrawal group; Table 1 and Fig. 1 ).
The taper group (N = 85)
The reasons given for the tapering decision are shown in Table 3 .
The duration of barbiturate therapy was considerably long in most of the patients: 63 patients (74%) had been on a barbiturate for more than 20 years (<5 years: 3 patients; 6-10 years: 4; 11-15 years: 7; 16-20 years: 8). Twenty-three patients had experienced earlier attempts to withdraw the barbiturate drug; these earlier attempts usually dated back for many years or had been carried out in the context of a different co-medication. Forty-one patients had one antiepileptic co-medication, 32 patients had two, 4 had three, and 2 patients had four antiepileptic drugs apart from the barbiturate. Six patients were on PB monotherapy. The most frequent therapy regimens were PB/ PRM + CBZ (20 patients), PB + LTG/VPA (12), PB + OCBZ (9), PB + PHT (5), PB + VPA (4); a number of other combinations occurred in less than 3 patients.
As mentioned above, for each patient an individual reduction pattern was determined (Table 4) . In many cases, however, the designed patterns could not exactly be adhered to. Delays resulted from complications of the tapering itself but were also due to independent medical conditions and personal circumstances. The actual reduction rate per 30 days was 14.1 AE 12.8 mg/d (x AE S.D.; range 1.9-62.5 mg/d). The reduction rate in serum concentration was 3.1 AE 3.8 mg/ml per 30 days (x AE S.D.; range 0.3-28.7 mg/ml). In those successfully withdrawn, the duration of the tapering procedure was 393 AE 266 days (x AE S.D.; range: 1-1330 days)
The withdrawal group (N = 72)
Of the 72 patients in whom PB/PRM was successfully withdrawn, polypharmacy (=number of AEDs prescribed per patient) was reduced in 61 patients. In the remaining 11 patients another AED had to be introduced instead of PB and, therefore, no reduction of polytherapy was achieved.
The results of the assessment of changes secondary to PB withdrawal are summarized in Tables 5-7 . Before the tapering, it was impossible in a majority of the patients to know whether they were impaired by their barbiturate medication. After withdrawal 68% of the patients were assessed as not being impaired by their remaining medication (Table 5 ).
An improvement in cognition, psychological state and/or behaviour attributed to withdrawal of PB occurred in 17 patients (23.6%) while no change was observed in 44 patients (61.1%), and 5 patients (6.9%) deteriorated (Table 6 ). 15 patients (20.8%) had a reduction in seizure frequency of different degree, 20 patients (27.8%) experienced an increase in seizures, while seizure frequency remained unchanged in 33 (45.8%; Table 6 ). The overall judgement (CGI) of the intervention showed an improvement of different degree in 25 patients (34.7%) while 31 patients (43.1%) remained unchanged and 12 (16.7%) worsened (Table 6 ).
An overview over the relation between cognitive/psychological changes, seizure frequency and overall judgement (CGI) is shown in Table 7 .
Changes in the concomitant medication (withdrawal group, N = 72)
The most frequent concomitant medications were CBZ (26 patients), VPA (23 patients), LTG (19) , OCBZ (12) and PHT (8) .
A great number of changes in co-medication happened. A considerable part of them was subsequent to PB pharmacokinetic interactions. In 24 patients the serum concentration of concomitant AED(s) increased (not caused by dosage change of that AED) due to the elimination of PB-related enzyme induction. While this led to toxicity in some cases, it improved seizure control in others. In 15 patients, the dosage of a concomitant AED had to be adjusted in order to keep the serum concentration stable (as a compensation for serum level changes caused by omission of interaction with PB).
Other changes independent of pharmacokinetic PB interactions were intended to improve seizure control in compensation for PB withdrawal. They included dosage increases in 15 patients and reductions in 11 patients. In 24 patients an AED was added to the medication (VPA and OCBZ 9 cases each, LTG 5 cases), and in 13 patients an AED (apart from PB) was discontinued (in 11 patients the discontinued AED was replaced with another AED; in 4 of these cases CBZ was replaced with OCBZ).
Co-medication remained unchanged in only 9 patients.
Improved patients
Twenty-five patients (34.7%) showed clinical improvement on PB withdrawal (Table 7 , slight/clear/comprehensive improvement). 12 of them experienced a decrease in seizure frequency, 15 were cognitively improved (Table 7 , columns with grey background). 4 Details of these patients are summarized in Table 8 . In most patients a combination of reasons was given. 4 The improved group includes two patients who had a slight seizure increase which was far outweighed by cognitive improvement, resulting in a positive CGI overall judgement. Vice versa, one patient (E.W. in Table 8 ) in the improved group was more verbally aggressive after PB withdrawal. As this happened only sometimes and could be managed by her environment it was thought to be minor seeing her seizure reduction. Therefore, the CGI overall judgement was positive.
3.5. Problems in the withdrawal group 3.5.1. Temporary problems Temporary problems, mostly but not exclusively withdrawal seizures, occurred in 33 of the 72 (45.8%) patients who discontinued PB (Table 9 ).
Lasting deterioration
Twenty-one patients deteriorated on PB withdrawal (CGI overall judgement), in most cases due to seizure increase but psychiatric/behavioural problems also occurred. For clinical details see Table 10 .
3.6. Patients in whom PB tapering failed (N = 13) Table 11 discloses details on the clinical course of the 13 patients in whom PB tapering failed due to seizure increase and/or other complications.
The outcome groups
For the purpose of statistical analysis we categorized the patients in three main outcome groups:
The improved group (N = 25): slight/clear/comprehensive in CGI overall judgement (Table 7 , columns with grey background) The unchanged group (N = 31); CGI overall judgement: unchanged (Table 7 , column ''unchanged''). Most of these patients remained completely unchanged despite PB discontinuation. In a few patients of this group results were contradictory or ambiguous (e.g., more seizures but better mood) resulting in an ''unchanged'' overall judgement. The deteriorated/failed group (N = 25) comprises the patients who clinically deteriorated on PB withdrawal (N = 12; Table 7 , column ''worse'') PLUS the patients in whom PB tapering had to be aborted/reversed (N = 13; Table 11 ).
Statistical analysis
Univariate statistical analysis indicated that outcome was significantly dependent on seizure frequency, age, earlier attempts of PB/PRM withdrawal and co-medication with CBZ or VPA. A high seizure frequency before tapering was related to good outcome (improvement), while seizure freedom was associated with deterioration/failure (p = 0.036). Older age was also associated with better outcome (p = 0.017), whereas a history of earlier attempts to withdraw PB/PRM was a strong predictor for deterioration/failure (p = 0.009). In terms of co-medication, outcome depended on the presence of CBZ (which was associated with improvement; p = 0.026) and VPA (which was associated with deterioration/ failure; p = 0.028), but not on the presence of LTG, OCBZ or PHT.
No relationship was found between outcome and epilepsy syndrome, degree of intellectual disability, number of concomitant AEDs, duration of barbiturate therapy, maximum dosage or serum Stepwise logistic regression revealed a history of an attempt to withdraw PB/PRM (p = 0.017; OR 3.8; CI 1.3-11.2), age (p = 0.012) and seizure frequency (only marginally significant: p = 0.097) as outcome predictors. CBZ or VPA were no longer significant (p > 0.1) when the predictors mentioned before were included in the logistic regression equation.
Seizure free patients
Of the 13 previously seizure free patients, the tapering had to be abandoned in 4 due to seizure recurrence. In 9 patients PB/PRM was completely withdrawn, 4 of them experienced seizures again. Only 5 patients remained seizure free. Only 1 patient had an improvement in her cognitive/psychological state ( Table 8 , patient E.G.).
Patients on PB monotherapy
Six patients were on PB monotherapy. In 2 of them the tapering had to be abandoned (C.T.; U.D., Table 11 ). In 3 patients PB was replaced with another AED (CBZ, OCBZ, VPA). Two of these patients experienced improvement of their psychological state, none of them showed a significant change in seizure frequency. One patient remained seizure free after his antiepileptic medication was completely discontinued.
Discussion
There is a history of barbiturate withdrawal trials. 4, 16, [29] [30] [31] [32] [33] [34] [35] [36] [37] Most of them were conducted before an increasing number of new AEDs became available in the 1990 years. Sometimes, other sedative AEDs besides barbiturates were also withdrawn, or barbiturate withdrawal occurred as part of a program to rationalise and reduce existing polypharmacy. [30] [31] [32] [33] [34] 37 In some of the trials, case numbers were low. [30] [31] [32] 36 Most of the publications pointed out that it was possible to reduce the use of barbiturates without seizure increase 16,31,33-36 but difficulties or failure to withdraw PB were also mentioned. [32] [33] [34] 37 Favourable effects on behaviour and cognition secondary to barbiturate removal were described 4, 34, 36 but in some work they were limited to a small number of patients. 16, 33 Occasionally, authors tended to downplay difficulties and complications of the withdrawal procedure. Our paper, which includes a relatively large number of patients, is one of few reports on barbiturate withdrawal in the era of the new AEDs. We have tried to draw a realistic picture of the achievements for individual patients but also of the multitude of problems that emerged. We are aware of some methodological limitations of our work. The reported changes in cognition, behaviour and mood mentioned are not based on formal neuropsychological testing, but on a relatively gross instrument, the CGI scale, and on clinical descriptions. On the other hand, this tool has the advantage to be applicable in patients with all degrees of intellectual impairment. The clinical descriptions, provided by Table 6 classes ''>50% seizure reduction'', ''25-50% seizure reduction'' and ''Seizure reduction (not quantifiable)''. b Includes Table 6 classes ''Unchanged'' and ''Remained seizure free''. c Includes Table 6 classes ''Seizure relapse (seizure free before)'', ''25-50% seizure increase'' ''>50% seizure increase'' and ''Seizure increase (not quantifiable)''. the staff neurologist/psychiatrist and the immediate care-takers, are likely to reflect changes which are relevant for daily functioning and for the patients' well-being. In several aspects, this work is based upon a very individualised approach. Decisions like the selection of patients required thorough consideration of different reasons pro and contra tapering. These reasons have to be weighted for the individual patient. Therefore, they could not be made in a standardized way but rather depended on the expert clinicians' careful judgement. A more standardized approach, although desirable from a scientific point of view, was also prevented by ethical and legal concerns. Similar considerations apply for the determination of the reduction rate. Furthermore, as any treatment has to be negotiated with patients, carers and legal representatives, their courage or fearfulness inevitably influenced the reduction rate. As for the moment to interrupt the tapering in case of problems arising, the clinical situations were too manifold to allow schematic decisions (e.g., interruption at 50% seizure increase), as is shown in Table 11 (tapering failed) as well as in Tables 9 and 10 (tapering continued despite problems during and after tapering).
After a careful clinical assessment of 191 patients on barbiturate therapy it seemed sensible to refrain from a tapering attempt for approximately one-half of the patients. The maintenance group includes more patients in the older age groups (Table 1) ; this was to be expected as older age had been a reason against tapering. More female patients remained on a barbiturate while clearly more men were in the withdrawal group (Table 1) ; we are not aware of any obvious medical reasons for this imbalance. The main reason to maintain patients on PB/PRM was seizure freedom. Nevertheless, 13 seizure free patients entered the tapering trial (Table 1 , columns withdrawal group and tapering failed group). The most prevalent reason to include these patients despite seizure freedom was very long duration of seizure control (decades) and, based upon that, the assumption of a low relapse risk. The results have confirmed that During PB reduction clusters of seizures but also long intervals occurred. After complete PB withdrawal: a marked increase of seizure activity which could not be stopped despite higher dosages of concomitant AED (LTG) ! admission to hospital. After 3 months in hospital without improvement he had to move from external apartment back into the residence (loss of independence). Needed a leather protective helmet. Cognitive abilities and daily life capabilities were reduced compared to status quo ante (9 months after stopping PB, after another unsuccessful AED trial, PB was re-introduced good seizure control is a strong risk factor for deterioration. We had to learn the lesson that long-term seizure control is no protection against relapses. In our organisation most doctors and carers have been familiar with the patients for years. Nevertheless, in more than half of the patients it was impossible to know whether or not they suffered from cognitive or psychological side effects before the tapering (Table 5 ). This difficulty is obviously inherent to any longstanding treatment with potentially sedating medications in persons with intellectual disability. Unlike in persons with average intellectual capacities, it can be impossible to discern whether a certain deficit has to be attributed to the person's handicap itself or to the drug prescribed. In such cases, the issue of adverse effects on cognition, attention, mood etc. can only be clarified through tapering the medication in question-unless the effects are irreversible. In this report, unexpectedly, only one out of four patients improved cognitively/psychologically after PB was withdrawn (Table 6) , while 61% remained unchanged. A possible explanation could be that patients on long-term therapy might have developed tolerance against adverse effects. It cannot be excluded, on the other hand, that some adverse effects had become irreversible during decade-long treatment. Moreover, it can be assumed that in patients who had more apparent cognitive impairment caused by PB or PRM, these drugs had already been withdrawn in an early stage of treatment. The types of change most frequently observed were improved alertness and better mood. Unfortunately, a small number of patients worsened cognitively. In 2 of these 5 patients, among them the one who worsened clearly (F.S. in Table 10 ), this happened in the context of seizure increase.
Tapering was carried out carefully and slowly (mean duration more than a year), and adaptations of the designed reduction pattern were made whenever seizure exacerbations impended. Nonetheless, nearly half of the patients (45.8%) had temporary problems during the tapering (Table 9 ). These problems included not only withdrawal seizures, a well-known phenomenon with barbiturates, but also behavioural changes, toxicity caused by drug interaction and, mainly in more severely handicapped multimorbid patients, unclear (possibly multifactorial) and difficult-tomanage clinical situations which were triggered by the tapering procedure (Table 9 ). Altogether, tapering of PB after long lasting therapy, carried out in the setting of residential homes, tended to be tedious and protracted. Since barbiturates have pharmacokinetic interactions with numerous (antiepileptic and other) drugs, a careful monitoring of concomitant medications during the tapering is mandatory. In our trial, the most typical situation was an increase in serum levels due to omission of PB-related enzyme induction. In these cases, clinicians had to decide whether to reduce the dosage of that respective AED. Even though these decisions could not be made in a formally standardized way, the following considerations were made routinely: Adverse effects and also a lack of benefit from the increased serum levels were reasons for dose reduction, while improved seizure control and lack of side effects were taken as reasons in favour of keeping the serum concentration increased.
Despite careful patient selection, we saw as many failures and deteriorations as patients who benefited from the tapering. Tables  10 and 11 illustrate the broad spectrum of deteriorations which by far exceeded an increase in the pure number of seizures but also included medical and psychiatric complications (whether related to withdrawal symptoms or not) as well as social sequelae. The elimination of sedation, although generally desirable, could have contributed to the exacerbation of aggression or behavioural disorder in some cases. Especially patients with well-controlled seizures were at high risk for relapse seizures while the chance of positive effects was low. Fortunately, only a minority of the patients suffered a lasting seizure increase. This was mainly because the tapering procedure was stopped when temporary problems could not be solved. Another important risk factor (nearly fourfold risk) was a history of an attempt to withdraw barbiturate medication. With these results, our conclusion is to except patients with well-controlled seizures and patients who had earlier withdrawal attempts from future efforts to reduce barbiturate medication.
In contrast, a high seizure frequency was associated with good outcome. One might assume that this could be due to regression to the mean. Patients with high seizure frequency might have improved in the context of normal fluctuations of their seizure frequency rather than dependent on medication change. However, we used exceptionally long spaces of time in this work. The seizure frequency before tapering was determined over a period of 1 year, the tapering procedure again averaged more than a year, and the post-evaluation period lasted 4 months. Spontaneous fluctuations of seizure numbers, on the contrary, usually occur rather in terms of months than of years. Older age was also associated with a better outcome. In our preselection, old age was rather an argument against tapering. By doing so we had mainly the propensity of senior persons to bone fractures and other medical complications in mind. Our results indicate, however, that old age per se is not a contraindication for barbiturate withdrawal.
Remarkably, no variable related to the barbiturate medication itself like duration of therapy, dosage, serum concentration, reduction rate was associated with outcome. Likewise, no diagnostic parameter like epilepsy syndrome or degree of intellectual disability was related to outcome.
We must conclude that we did succeed in reducing considerably the number of barbiturate medications in our resident population, but that the principal aim of the project, to relieve patients from assumed barbiturate side effects, has been achieved only in one out of four patients. The multitude of problems and complications experienced is a reminder that the decision to taper barbiturate medication after long-term treatment should be made prudently.
